LAUNXP Biomedical Co., Ltd (TPEX:6876)
Taiwan
· Delayed Price · Currency is TWD 19.90
-0.60 (-2.93%)
Apr 29, 2026, 2:00 PM CST
LAUNXP Biomedical Company Description
LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients.
It develops various drugs, which are in preclinical stage, including LXP5948 for non-small cell lung cancer and Alzheimer's disease; LXP5268 for triple negative breast cancer; LXP5101 for pancreatic cancer; LXP1788 for gastrointestinal cancer; and Virus-like particles for cancer and genetic defect treatment.
The company was founded in 2015 and is based in Taichung, Taiwan.
LAUNXP Biomedical Co., Ltd
| Country | Taiwan |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Chiu-Heng Chen |
Contact Details
Address: B1 Room, No. 51, Section 2 Taichung, 408 Taiwan | |
| Phone | 886 4 2320 5691 |
| Website | launxp.com |
Stock Details
| Ticker Symbol | 6876 |
| Exchange | Taipei Exchange |
| Reporting Currency | TWD |
| ISIN Number | TW0006876006 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Chiu-Heng Chen | President, Chief Executive Officer and Director |
| Shi-Feng Yan | Vice President of Finance and Director of Accounting Department |
| Connie Yang | Chief Technology Officer |
| Aileen Hsu | Chief of Staff |